Appointment of Vice President of Investor Relations

CAMBRIDGE, England, June 27, 2022 /PRNewswire/ — Abcam plc (“Abcam”, “Company”, “Group”) (AIM: ABC) (Nasdaq: ABCM), a world leader in the provision of life science research tools, today announces the appointment of TomThomas as Vice President of Investor Relations.

Abcam Logo

Tommy, who will be based in our Waltham, MA bureau, has over 20 years of experience in the life sciences industry, primarily focused on research tools. He joins Abcam from Avantor, where he served as vice president of investor relations for several years. Previously, he was vice president of investor relations and then chief financial officer of global services at Perkin Elmer. Prior to joining Perkin Elmer, Tommy spent eight years as a buy-side analyst for TIAA-CREF, specializing in the areas of medical technology and life science tools.

Michael BaldockAbcam’s chief financial officer, said: “I am delighted to have Tommy join us. His deep industry experience, significant investor relations expertise and strong relationships with institutional investors and research analysts are a big step forward for us. Tommy will be a a real asset to Abcam and our investors as we continue to grow, differentiate ourselves in the market and bring value to all our stakeholders.”

TomThomas commented: “I am very pleased to join Abcam at this important time in its evolution. The company’s customer-centric model, focused on innovating new products for researchers and clinicians in the life science industry, is very differentiated. I look forward to learning and telling our story as I make new friendships along the way.”

About Abcam plc

As an innovator in reagents and tools, Abcam’s goal is to help life science researchers around the world achieve their mission faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to target important targets in critical biological pathways.

Already a pioneer in data sharing and e-commerce in the life sciences, Abcam’s ambition is to be the most influential company in the life sciences by helping to advance the global understanding of biology and causes of disease, which in turn will lead to new treatments and better health.

Abcam’s global customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company is continually evolving its portfolio to meet their needs. A transparent customer review and datasheet program, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and based in Cambridge, UK, the company has served customers in over 130 countries. Abcam’s ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADS) trade on the Nasdaq Global Market (Nasdaq: ABCM).

Please visit company.abcam.com to know more.

SOURCEAbcam plc

Comments are closed.